NASDAQ · Health care

Veraxa Biotech Holding AG (VRXA)

We have not processed filings for Veraxa Biotech Holding AG yet. This page fills in on its own once we have read them.

What Veraxa Biotech Holding AG does

Veraxa Biotech Holding AG is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VRXA.

Latest SEC filings

What Veraxa Biotech Holding AG has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 4, 2026
Securities offering prospectus 424B3
September 4, 2026
Securities offering prospectus 424B3
September 4, 2026
Foreign issuer update 6-K
August 24, 2026
Foreign issuer update 6-K
August 13, 2026
Passive stake changed SCHEDULE 13G/A
August 10, 2026
Securities offering prospectus 424B5
August 10, 2026
Securities offering prospectus 424B5
August 5, 2026
IPO registration (foreign issuer) (amended) F-1/A
August 5, 2026
IPO registration (foreign issuer) (amended) F-1/A
July 31, 2026
IPO registration (foreign issuer) F-1

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 14, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about VRXA

What does Veraxa Biotech Holding AG do?

Veraxa Biotech Holding AG is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VRXA.

When did Veraxa Biotech Holding AG last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on June 16, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the new insider holdings from September 14, 2026.

Similar companies

Follow VRXA

Get an email when Veraxa Biotech Holding AG files with the SEC: results, executive changes, material agreements and annual reports.

Follow VRXA: get an email when it files

Where the numbers come from

Financial figures are the values Veraxa Biotech Holding AG tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.